Lesion mechanism dependent, differential changes in neurofilaments and microtubules: A pathological and experimental study;Modifications des neurofilaments et des microtubules axonaux en fonction du mécanisme lésionnel: Étude pathologique et expérimentale

Revue Neurologique

Volumn 161, Issue 1, 2005, Pages 55-60

  Fressinaud, C ^a   Jean, I ^a   Dubas, F ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic inflammatory demyelinating neuropathy; Multiple sclerosis; Neurofilament; Tubulin

Indexed keywords

BETA TUBULIN; LYSOPHOSPHATIDYLCHOLINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; CELL DENSITY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS CALLOSUM; CORRELATION ANALYSIS; CYTOSKELETON; DEMYELINATING DISEASE; DEMYELINATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MICROINJECTION; MICROTUBULE; MULTIPLE SCLEROSIS; NECROTIZING ARTERITIS; NERVE BIOPSY; NERVE FIBER; NERVE FIBER DEGENERATION; NEUROFILAMENT; NONHUMAN; RAT;

EID: 13244270090     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(05)84973-2     Document Type: Article

References (20)

1. AD Hoc SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY AIDS TASK FORCE. (1991). Research criteria for the diagnosis of chronic inflammatory demyelinating polyneuropathy. Neurology, 41: 617-618.
2. ALLAMARGOT C, POUPLARD-BARTHELAIX A, FRESSINAUD C. (2001). A single intracerebral injection of platelet-derived growth factor (PDGF) accelerates the rate of remyelination in vivo. Brain Res, 918: 28-39.
3. FRESSINAUD C, VALLAT JM. (1994). Chimie du nerf périphé rique. Éditions Techniques, Encycl Méd Chir (Paris), Neurologie, 17-030-F-10, 1994, 5 p.
4. FRESSINAUD C, JEAN I. (2002). Polyradiculonévrites inflammatoires chroniques et cytosquelette axonal: données morphométriques et immunocytochimiques. Rev Neurol (Paris), 158: 713-718.
5. FRESSINAUD C, VIGNERON I, LETOURNEL F, NICOLAS G, JEAN I, DUBAS F. (2002). Cytoskeleton abnormalities in axonopathies of unknown aetiology: correlations with morphometry. J Neurol Sci 196: 53-61.
6. FRESSINAUD C, JEAN I. (2003). Axonal cytoskeleton and oligodendrocyte alterations in MS. J Neurochem, 85 (Suppl. 1): Abstract OP3-01 p. 100.
7. FRESSINAUD C, JEAN I, DUBAS F. (2003a). Vascularites nécrosantes du système nerveux périphérique: comparaison des anomalies du cytosquelette axonal avec d'autres types de neuropathies. Rev Neurol (Paris), 159: 293-299.
8. FRESSINAUD C, JEAN I, DUBAS F. (2003b). Selective decrease in axonal nerve growth factor and insulin-like growth factor I immunoreactivity in axonopathies of unknown etiology. Acta Neuropathol (Berlin), 105: 477-483.
9. HAQ RU, FRIES TJ, PENDLEBURY WW, KENNY MJ, BADGER GJ, TANDAN R. (2000). Chronic inflammatory demyelinating polyradiculoneuropathy. A study of proposed electrodiagnostic and histologic criteria. Arch Neurol, 57: 1745-1750.
10. HOFFMAN PN, CLEVELAND DW. (1988). Neurofilament and tubulin expression recapitulates the developmental program during axonal regeneration: induction of a specific β-tubulin isotype. Proc Natl Acad Sci USA, 85: 4530-4533.
11. JEAN I, ALLAMARGOT C, BARTHELAIX-POUPLARD A, FRESSINAUD C. (2002). Axonal lesions and PDGF-enhanced remyelination in the rat corpus callosum after lysolecithin demyelination. Neuroreport, 13: 627-631.
12. LUNN MPT, CRAWFORD TO, HUGHES RAC, GRIFFIN JW, SHEIKH KA. (2002). Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain, 125: 904-911.
13. MOHIUDDIN L, FERNYHOUGH P, TOMLINSON R. (1995). Reduced levels of mRNA encoding endoskeletal and growth-associated proteins in sensory ganglia in experimental diabetes. Diabetes, 44: 25-30.
14. MUMA NA, HOFFMAN PN, SLUNT HH, APPLEGATE MD, LIEBERBURG I, PRICE DL. (1990). Alterations in levels of mRNAs coding for neurofilament protein subunits during regeneration. Exp Neurol, 107: 230-235.
15. Sobue G, Li M, Terao S, et al. (1997). Axonal pathology in Japanese Guillain-Barré syndrome: a study of 15 autopsied cases. Neurology, 48: 1694-1700.
16. Strong MJ, Mao K, Nerurkar VR, Wakayama I, Yanagihara R, Garruto RM. (1994) Dose-dependent selective suppression of light (NFL) and medium (NFM) but not heavy (NFH) molecular weight neurofilament mRNA levels in acute aluminium neurotoxicity. Mol Cell Neurosci, 5: 319-326.
17. TRAPP BD, PETERSON J, RANSOHOF RM, RUDICK R, MÖRK S, BÖ L. (1998). Axonal transection in the lesions of multiple sclerosis. N Engl J Med, 338: 278-285.
18. TROJANOWSKI JQ, LEE VMY, SCHLAEPFER WW. (1984). Neurofilament breakdown products in degenerating rat and human peripheral nerves. Ann Neurol, 16: 349-355.
19. VITAL A, VITAL C. (1985). Polyarteritis nodosa and peripheral neuropathy. Ultrastructural study of 13 cases. Acta Neuropathol (Berl), 67: 136-141.
20. WATSON DF, NACHTMAN FN, KUNCL RW, GRIFFIN JW. (1994). Altered neurofilament phosphorylation and beta tubulin isotypes in Charcot-Marie-Tooth disease type 1. Neurology, 44: 2383-2387.